Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026

Core Insights - Molecular Partners AG has presented promising first patient imaging and dosimetry data for its DLL3-targeted Radio-DARPin candidate MP0712 at the 8th Theranostics World Congress, indicating strong potential for treating small cell lung cancer and other DLL3-expressing neuroendocrine cancers [1][2][4] Clinical Development - The data from five evaluable patients show favorable tumor uptake of MP0712 with limited uptake in healthy tissues, supporting its therapeutic potential [2][3] - The biodistribution and dosimetry data validate the ongoing U.S. Phase 1/2a study of MP0712, which aims to assess safety and determine a recommended phase 2 dose [4][5] Presentation Details - Two posters and an oral presentation were made at the congress, highlighting the specific tumor accumulation and dosimetry data that support the clinical development of MP0712 [5][7] - The oral presentation titled "From DARPins to Radio-DARPin Therapeutics" was scheduled for January 31, 2026, focusing on the progress of MP0712 [7] Future Outlook - Initial clinical data from the Phase 1/2a study of MP0712 is expected in 2026, with the company planning to share safety and activity data as the study progresses [4][5] - The company aims to establish itself as a leader in alpha-targeted therapies for small cell lung cancer and neuroendocrine malignancies [4]